Boosting antibody responses by targeting antigens to dendritic cells

Irina Caminschi, Ken Shortman

Research output: Contribution to journalReview ArticleResearchpeer-review

55 Citations (Scopus)

Abstract

Delivering antigens directly to dendritic cells (DCs) in situ, by injecting antigens coupled to antibodies specific for DC surface molecules, is a promising strategy for enhancing vaccine efficacy. Enhanced cytotoxic T cell responses are obtained if an adjuvant is co-administered to activate the DC. Such DC targeting is also effective at enhancing humoral immunity, via the generation of T follicular helper cells. Depending on the DC surface molecule targeted, antibody production can be enhanced even in the absence of adjuvants. In the case of Clec9A as the DC surface target, enhanced antibody production is a consequence of the DC-restricted expression of the target molecule. Few other cells absorb the antigen-antibody construct, therefore, it persists in the bloodstream, allowing sustained antigen presentation, even by non-activated DCs.

Original languageEnglish
Pages (from-to)71-77
Number of pages7
JournalTrends in Immunology
Volume33
Issue number2
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Cite this

@article{6288323b4c694fb687a041062a3d2a0f,
title = "Boosting antibody responses by targeting antigens to dendritic cells",
abstract = "Delivering antigens directly to dendritic cells (DCs) in situ, by injecting antigens coupled to antibodies specific for DC surface molecules, is a promising strategy for enhancing vaccine efficacy. Enhanced cytotoxic T cell responses are obtained if an adjuvant is co-administered to activate the DC. Such DC targeting is also effective at enhancing humoral immunity, via the generation of T follicular helper cells. Depending on the DC surface molecule targeted, antibody production can be enhanced even in the absence of adjuvants. In the case of Clec9A as the DC surface target, enhanced antibody production is a consequence of the DC-restricted expression of the target molecule. Few other cells absorb the antigen-antibody construct, therefore, it persists in the bloodstream, allowing sustained antigen presentation, even by non-activated DCs.",
author = "Irina Caminschi and Ken Shortman",
year = "2012",
month = "2",
doi = "10.1016/j.it.2011.10.007",
language = "English",
volume = "33",
pages = "71--77",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier",
number = "2",

}

Boosting antibody responses by targeting antigens to dendritic cells. / Caminschi, Irina; Shortman, Ken.

In: Trends in Immunology, Vol. 33, No. 2, 02.2012, p. 71-77.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Boosting antibody responses by targeting antigens to dendritic cells

AU - Caminschi, Irina

AU - Shortman, Ken

PY - 2012/2

Y1 - 2012/2

N2 - Delivering antigens directly to dendritic cells (DCs) in situ, by injecting antigens coupled to antibodies specific for DC surface molecules, is a promising strategy for enhancing vaccine efficacy. Enhanced cytotoxic T cell responses are obtained if an adjuvant is co-administered to activate the DC. Such DC targeting is also effective at enhancing humoral immunity, via the generation of T follicular helper cells. Depending on the DC surface molecule targeted, antibody production can be enhanced even in the absence of adjuvants. In the case of Clec9A as the DC surface target, enhanced antibody production is a consequence of the DC-restricted expression of the target molecule. Few other cells absorb the antigen-antibody construct, therefore, it persists in the bloodstream, allowing sustained antigen presentation, even by non-activated DCs.

AB - Delivering antigens directly to dendritic cells (DCs) in situ, by injecting antigens coupled to antibodies specific for DC surface molecules, is a promising strategy for enhancing vaccine efficacy. Enhanced cytotoxic T cell responses are obtained if an adjuvant is co-administered to activate the DC. Such DC targeting is also effective at enhancing humoral immunity, via the generation of T follicular helper cells. Depending on the DC surface molecule targeted, antibody production can be enhanced even in the absence of adjuvants. In the case of Clec9A as the DC surface target, enhanced antibody production is a consequence of the DC-restricted expression of the target molecule. Few other cells absorb the antigen-antibody construct, therefore, it persists in the bloodstream, allowing sustained antigen presentation, even by non-activated DCs.

UR - http://www.scopus.com/inward/record.url?scp=84856557403&partnerID=8YFLogxK

U2 - 10.1016/j.it.2011.10.007

DO - 10.1016/j.it.2011.10.007

M3 - Review Article

AN - SCOPUS:84856557403

VL - 33

SP - 71

EP - 77

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 2

ER -